We are strategically partnering with world-class life science companies, as well as academic researchers, to develop a portfolio of 3D bioprinted human tissues. These tissues are advancing drug development by providing predictive pre-clinical models and enabling regenerative medicine through the development of implantable tissue therapies.LEARN MORE
Our team is driving a fundamental shift in the life sciences through the broad application of it’s unique 3D bioprinting technology to make this future a reality.ABOUT US
Our 3D bioprinting platform enables the rapid creation of 3D heterogeneous, structurally accurate, and functional tissues. Our technology uses a multifunctional microfluidic printhead capable of programmatically manipulating and sequencing multiple biomaterials, living cells, extracellular matrix content, growth factors, bioactive compounds and other bioinks ‘on the fly’ during tissue printing.SEE MORE
The RX1™ 3D Bioprinter merges critical advancements in 3D printing and microfluidics to accurately capture the detail required to recreate complex human tissues.Learn More
This $2.2M project is made possible by contributions from CQDM, CCS, Merck, GSK, Aspect Biosystems, and McGill University.
Aspect Biosystems Named 2019 Growth Stage Company of the Year by LifeSciences BC.